UY27419A1 - Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización. - Google Patents

Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización.

Info

Publication number
UY27419A1
UY27419A1 UY27419A UY27419A UY27419A1 UY 27419 A1 UY27419 A1 UY 27419A1 UY 27419 A UY27419 A UY 27419A UY 27419 A UY27419 A UY 27419A UY 27419 A1 UY27419 A1 UY 27419A1
Authority
UY
Uruguay
Prior art keywords
active substances
formulations
derivatives
combination
benzotiepina
Prior art date
Application number
UY27419A
Other languages
English (en)
Spanish (es)
Inventor
Dr Heiner Glombik
Dr Hans-Ludwig Schafer
Dr Werner Kramer
Dr Wendelin Frick
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140169A external-priority patent/DE10140169A1/de
Priority claimed from DE10142456A external-priority patent/DE10142456A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY27419A1 publication Critical patent/UY27419A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D337/00Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02Seven-membered rings
    • C07D337/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
UY27419A 2001-08-22 2002-08-20 Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización. UY27419A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10140169A DE10140169A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von 1,4-Benzothiepin-1,1-dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung
DE10142456A DE10142456A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von 1,4-Benzothiepin-1,1dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
UY27419A1 true UY27419A1 (es) 2003-04-30

Family

ID=26009944

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27419A UY27419A1 (es) 2001-08-22 2002-08-20 Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización.

Country Status (29)

Country Link
US (2) US20030158119A1 (https=)
EP (1) EP1425018B1 (https=)
JP (1) JP2005501861A (https=)
KR (1) KR20040032937A (https=)
CN (1) CN1655792A (https=)
AR (1) AR035285A1 (https=)
AT (1) ATE411802T1 (https=)
AU (1) AU2002333373B2 (https=)
BR (1) BR0212031A (https=)
CA (1) CA2457976A1 (https=)
CO (1) CO5560550A2 (https=)
DE (1) DE50212937D1 (https=)
HN (1) HN2002000235A (https=)
HR (1) HRP20040171A2 (https=)
HU (1) HUP0401318A3 (https=)
IL (1) IL160474A0 (https=)
MA (1) MA26317A1 (https=)
MX (1) MXPA04001328A (https=)
NO (1) NO20040702L (https=)
NZ (1) NZ531293A (https=)
OA (1) OA12654A (https=)
PA (1) PA8553201A1 (https=)
PE (1) PE20030361A1 (https=)
PL (1) PL366851A1 (https=)
RS (1) RS11104A (https=)
RU (1) RU2297222C2 (https=)
TN (1) TNSN04034A1 (https=)
UY (1) UY27419A1 (https=)
WO (1) WO2003018024A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053637B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE502007006208D1 (de) 2006-11-14 2011-02-17 Sanofi Aventis Deutschland Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
US9339543B2 (en) 2011-10-12 2016-05-17 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
KR20020002367A (ko) * 1998-12-23 2002-01-09 윌리암스 로저 에이 심혈관 징후를 위한 조합물
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1204654B1 (en) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
ATE369337T1 (de) 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use

Also Published As

Publication number Publication date
HUP0401318A3 (en) 2008-03-28
KR20040032937A (ko) 2004-04-17
JP2005501861A (ja) 2005-01-20
NZ531293A (en) 2005-08-26
RU2004108119A (ru) 2005-04-10
DE50212937D1 (de) 2008-12-04
AU2002333373B2 (en) 2006-12-14
IL160474A0 (en) 2004-07-25
MXPA04001328A (es) 2004-05-05
CO5560550A2 (es) 2005-09-30
ATE411802T1 (de) 2008-11-15
AR035285A1 (es) 2004-05-05
HRP20040171A2 (en) 2004-10-31
WO2003018024A1 (de) 2003-03-06
PA8553201A1 (es) 2004-08-31
US7179792B2 (en) 2007-02-20
RS11104A (sr) 2006-12-15
NO20040702L (no) 2004-05-19
MA26317A1 (fr) 2004-10-01
CN1655792A (zh) 2005-08-17
HN2002000235A (es) 2003-02-18
RU2297222C2 (ru) 2007-04-20
OA12654A (en) 2006-06-15
HUP0401318A2 (hu) 2004-10-28
US20030158119A1 (en) 2003-08-21
PL366851A1 (en) 2005-02-07
PE20030361A1 (es) 2003-05-27
EP1425018A1 (de) 2004-06-09
TNSN04034A1 (en) 2006-06-01
EP1425018B1 (de) 2008-10-22
BR0212031A (pt) 2004-08-03
CA2457976A1 (en) 2003-03-06
US20040097424A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
UY27419A1 (es) Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización.
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
PA8553001A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos.
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
CR8278A (es) Combinaciones sinergicas de productos activos, fungicidas
UY27350A1 (es) Azaindoles
ECSP055531A (es) "nuevos derivados de glicósido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso"
HN2002000247A (es) Derivados de sulfonamida
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
CR9587A (es) Derivados de piridazina
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY28732A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparación y su uso como medicamentos.
CR9703A (es) Derivados de pirazolona
MX2010006436A (es) Derivados peptidos mimeticos de eritropoyetina y sus sales farmaceuticas, su preparacion y usos.
CO5560515A2 (es) Combinacion de productos activos fungicidas
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
BR0209440A (pt) Sulfonamidas
AR063027A1 (es) Derivados de sulfonamida
PA8579301A1 (es) Derivados de tiazol
PA8581701A1 (es) Derivados de indolilo
BR0113581A (pt) Derivados de aril-piperazinas e seu uso como psicofármacos
EP1995249A4 (en) CAMPTOTHECIN DERIVATIVES AND THEIR USE
DE60129600D1 (de) Pleuromutilinderivate mit antimikrobieller wirkung

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20111122